ClinicalTrials.gg
RecruitingNCT05231785Updated Nov 12, 2026

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

A Phase 1 interventional study of ALN-APP and Placebo in Early-Onset Alzheimer Disease, sponsored by Alnylam Pharmaceuticals. Recruiting at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Alnylam Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.
Updated Oct 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Planned enrollment
866th of 1,609
60 · median 73
Started
2022
with 130 others
Phase 1
304 of 1,940
31 open now
Primary completion
2029-01
later than 355 of 444 live
Registered
1,423rd of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 866th largest by planned enrollment of the 1,609 interventional ones that give a count, is one of 131 that started in 2022, is one of 304 in phase 1, reaches primary completion later than 355 of the 444 other live ones, and was the 1,423rd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part B: 12 months.

03

Conditions studied

  • Early-Onset Alzheimer Disease

Browse trials for

Keywords

  • EOAD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has mild cognitive impairment or mild dementia due to EOAD
  • Has Clinical Dementia Rating (CDR) global score 0.5 or 1.0 and (MMSE) >20

Exclusion criteria

Exclusion Criteria:

  • Has Non-Alzheimer's disease dementia
  • Has (ALT) or aspartate aminotransferase (AST) >2× (ULN)
  • Has estimated (eGFR) \<45 mL/min/1.73m\^2 at Screening
  • Has recently received an agent
  • Has recent treatment with amyloid-targeting antibody

Note: other protocol defined inclusion / exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Part A: ALN-APP

    Participants will be administered a single dose of ALN-APP.

    Drug: ALN-APP

  • Placebo comparator
    Part A: Placebo

    Participants will be administered a single dose of placebo.

    Drug: Placebo

  • Experimental
    Part B:

    Participants will be administered multiple doses of ALN-APP.

    Drug: ALN-APP

Interventions

  • ALN-APP will be administered intrathecally (IT)

    Also known as: mivelsiran

  • DrugPlacebo

    Placebo will be administered IT

06

What researchers measure

Primary outcomes

  1. Part A: Frequency of Adverse Events

    Time frame: Up to 12 months

  2. Part B: Frequency of Adverse Events

    Time frame: Up to 42 months

Secondary outcomes

  1. Part A and Part B: Change from Baseline in Levels of Cerebrospinal Fluid (CSF) Soluble Amyloid Precursor Protein Alpha (sAPPα) and Soluble Amyloid Precursor Protein Beta (sAPPβ)

    Time frame: Part A up to 12 months; Part B up to 24 months

  2. Part A and Part B: Area Under the Plasma Concentration-time Curve (AUC) of ALN-APP and of Potential Metabolites

    Time frame: Part A up to 12 months; Part B up to 24 months

  3. Part A and Part B: Maximum Observed Plasma Concentration (Cmax) of ALN-APP and of Potential Metabolites

    Time frame: Part A up to 12 months; Part B up to 24 months

  4. Part A: Fraction of ALN-APP and Potential Metabolites Excreted in the Urine (fe)

    Time frame: Up to 1 day

  5. Part A and Part B: Concentration of ALN-APP and Potential Metabolites at Time 't' (Ct) in Plasma and CSF

    Time frame: Part A up to 12 months; Part B up to 24 months

07

Study locations

6 of 8 sites recruiting
  • Clinical Trial Site
    La Jolla, California 92037, United States
    Completed

    Not enrolling at this site.

  • Clinical Trial Site
    Indianapolis, Indiana 46202, United States
    Recruiting
  • Clinical Trial Site
    Montreal, H3A 2B4, Canada
    Recruiting
  • Clinical Trial Site
    Toronto, M3B 2S7, Canada
    Recruiting
  • Clinical Trial Site
    Amsterdam, 1081 BT, Netherlands
    Recruiting
  • Clinical Trial Site
    Groningen, 9713 GG, Netherlands
    Completed

    Not enrolling at this site.

  • Clinical Trial Site
    Huntley Street, WC1E 6AG, United Kingdom
    Recruiting
  • Clinical Trial Site
    Sheffield, S10 2JF, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Jan 2029, 83 months after the start.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 83 months is above that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Apr 2029 → Jan 2029 and completion Apr 2029 → Jan 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2022
First posted
Feb 9, 2022
StartActual
Feb 4, 2022
Primary completionEst.
Jan 11, 2029was Apr 2029
CompletionEst.
Jan 11, 2029was Apr 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 20, 2029→Jan 11, 2029
Oct 20, 2026
Study completion
Apr 20, 2029→Jan 11, 2029
Oct 20, 2026
Show all 2 updates
  1. Nov 12, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Oct 20, 2026
    Primary completion Apr 20, 2029→Jan 11, 2029
    Study completion Apr 20, 2029→Jan 11, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05231785
Responsible party
Sponsor
First posted
Feb 9, 2022
Start date
Feb 4, 2022
Primary completion
Jan 11, 2029 (estimated)
Completion
Jan 11, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Alnylam Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-ALNYLAM
Alnylam Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-256-9526
Medical Director
study director · Alnylam Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mivelsiran

Start the discussion